logo-loader
viewInstem PLC

Instem continues to benefit from a buoyant market

The company has established a highly scalable platform with improved operational gearing as growth is delivered.

Instem PLC -

Instem PLC (LON:INS), the provider of information technology solutions to the life sciences market, saw strong organic revenue growth in 2019.

Strong performance across the group's operations, combined with healthy new business pipelines, underpin management's confidence that the momentum achieved during 2019 will continue into the current year.

The company revealed that revenues in 2019 were around 12% higher than in 2018 with underlying earnings (EBITDA) in line with management's expectations.

Recurring revenues increased as the company continues to make the transition towards a software-as-a-service (SaaS) business model.

The Data Collection, Regulatory Solutions and Informatics divisions all performed well.

Instem highlighted the progress of the Informatics division, where the increasing use of artificial intelligence (AI) across the pharmaceutical intelligence plays to the division's strengths.

Growing demand for target safety assessments has been core to this business and is now complemented by November's earnings enhancing acquisition of Leadscope, which extends the company's reach, provides strong cross-selling opportunities and improves the visibility of earnings, Instem said, adding that the Leadscope integration plan is progressing well.

Meanwhile, as expected, the combination of regulation and repeat orders accounted for continued strong growth within Instem's SEND (Standard for the Exchange of Non-clinical Data) technology-enabled outsourced services.

In addition, the group's Study Management business benefited from further increases in order volume with recurring revenue and renewal rates remaining high.

Instem ended the year with net cash of £5.9mln.

"The company continues to benefit from a buoyant market and remains well placed across all parts of the life sciences industry, from discovery to post-marketing,” said Phil Reason, the chief executive officer of Instem.

“We have developed a strategy that sees the business benefiting from increasing levels of recurring revenues and a broad portfolio of products, enabling increased cross-selling opportunities. Added to this, the move to SaaS provides for improved margins and quality of earnings,” he added.

Quick facts: Instem PLC

Price: 530 GBX

AIM:INS
Market: AIM
Market Cap: £88.37 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Instem PLC named herein, including the promotion by the Company of Instem PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: CentralNic Group looks to acquire website provider Team...

Headlines from the Proactive UK newsroom. CentralNic Group (LON:CNIC) has confirmed advanced discussions are underway to acquire website provider Team Internet. The AIM-listed domain name specialist said further announcements will be made in due course. Life sciences group Instem (LON:INS)...

on 15/11/19

2 min read